<DOC>
	<DOCNO>NCT00384982</DOCNO>
	<brief_summary>The MYocardial STem cell Administration acute myocardial infaRction ( MYSTAR ) study multicenter , prospective , randomize , single-blind clinical trial design compare early late intracoronary combine ( percutaneous intramyocardial intracoronary ) administration bone marrow-derived stem cell patient acute myocardial infarction reopen infarct-related artery .</brief_summary>
	<brief_title>Myocardial Stem Cell Administration After Acute Myocardial Infarction ( MYSTAR ) Study</brief_title>
	<detailed_description>Previous data suggest bone marrow-derived stem cell ( BM-SCs ) decrease infarct size beneficially affect postinfarction remodel . The MYocardial STem cell Administration acute myocardial infaRction ( MYSTAR ) study multicenter , prospective , randomize , single-blind clinical trial design compare early late intracoronary combine ( percutaneous intramyocardial intracoronary ) administration BM-SCs patient acute myocardial infarction ( AMI ) reopen infarct-related artery . The primary endpoint change rest myocardial perfusion defect size leave ventricular ejection fraction ( gate SPECT scintigraphy ) 3 month BM-SCs therapy . The secondary endpoint relate evaluation 1 ) safety feasibility application mode , 2 ) change leave ventricular wall motion score index ( transthoracic echocardiography ) , 3 ) myocardial voltage segmental wall motion ( NOGA mapping ) , 4 ) leave ventricular end-diastolic end-systolic volume ( contrast ventriculography ) , 5 ) clinical symptom ( CCS NYHA ) follow-up . Patients randomly assign one four group , Group A : early treatment ( 21-42 day AMI ) intracoronary injection ; Group B : early treatment ( 21-42 day AMI ) combine ( intramyocardial intracoronary ) application ; Group C : late treatment ( 3 month AMI ) intracoronary delivery ; Group D : late treatment ( 3 month AMI ) combine ( intramyocardial intracoronary ) administration BM-SCs . Besides BM-SCs therapy , standardize treatment AMI apply patient . The MYSTAR trial first randomize trial investigate effect combine ( intramyocardial intracoronary ) intracoronary mode delivery BM-SCs therapy early late period AMI .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<criteria>Patient definitive AMI earlier 21 day later 42 day randomization ( day 0 day infarction ) Patients open IRA without significant stenosis TIMI flow 3 , successful percutaneous coronary intervention ( PCI ) IRA Patients two threevessel disease might include adequate PCI significant coronary lesion see noninfarctrelated major vessel time BMSCs therapy A persistent local new wall motion abnormality relate recent infarct location . Preserved myocardial viability , least part recent infarction demonstrate preserve wall thickness and/or hypokinesia determine transthoracic echocardiography contrast ventriculography , preserve tracer uptake determine early late resting Thallium myocardial scintigraphy FDGPET . Global LVEF 30 45 % . Written informed consent . Previous heart surgery Small posterior inferior AMI Previous MI location Regional wall motion abnormality outside area involve index AMI Ventricular thrombus Severe valvular heart disease Severe renal , lung liver disease Disease hematopoetic system Hemoglobin level 9 mg % The patient follow study protocol NYHA functional class IV baseline Postinfarct angina Significant coronary stenosis IRA require repeat PCI time plan BMSCs therapy Significant coronary lesion one major coronary vessel , require revascularization Age low 18 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>Bone marrow-derived stem cell</keyword>
	<keyword>Acute myocardial infarction</keyword>
</DOC>